Barry S. Cooperman is Professor of Chemistry at the University of Pennsylvania and the first collaborator of Anima around PSM technology. He received a B.A. in Chemistry from Columbia University, a Ph.D. in Chemistry from Harvard University, and postdoctoral work at the Pasteur Institute (Paris) before coming to Penn as an Assistant Professor. During his time at Penn he has served as Vice President for Research for 13 years, member of the International Scientific Advisory Board of Max-Planck-Institut für Molekulare Genetik, Berlin, as Regional Editor for the journal Biochimie, and as Chairman of the Board of Trustees of AUI and of the Scientific Advisory Committee of the Wistar Institute. He is a Fellow of the American Association for the Advancement of Science and a Chevalier de l'Ordre des Palmes Académique. His research interests focus on mechanistic biochemistry, with particular emphasis on the development of fluorescent probes for bothin vitroandin vivomonitoring of protein synthesis on the ribosome. Over the course of his career he has published more than 225 peer-reviewed papers and trained more than 80 graduate students and postdoctoral fellows. Since 2014 he is a member of the board of trustees of the Gordon Research Conferences.
Ada Yonath, PhD.
Ada Yonath is the current Director of the Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly of the Weizmann Institute of Science. She is a crystallographer best known for her pioneering work on the structure of the ribosome. In 2009, she received the Nobel Prize in Chemistry along with V. Ramakrishnan and T. A. Steitz, for her studies on the structure and function of the ribosome, becoming the first Israeli woman to win the Nobel Prize out of ten Israeli Nobel laureates, the first woman from the Middle East to win a Nobel prize in the sciences, and the first woman in 45 years to win the Nobel Prize for Chemistry. She accepted postdoctoral positions at the Carnegie Mellon University (1969) and MIT (1970). She headed a Max-Planck Institute Research Unit at DESY in Hamburg, Germany (1986–2004) in parallel to her research activities at the Weizmann Institute. She is a member of the United States National Academy of Sciences; the American Academy of Arts and Sciences; the Israel Academy of Sciences and Humanities; the European Academy of Sciences and Art and the European Molecular Biology Organization. Ada is a member of Anima's SAB since 2009.
Michel Goldberg, PhD.
Michel Goldberg is currently Professor Emeritus at Institut Pasteur (Paris – France). In addition to 43 years of basic research at this institute in the areas of enzymology and protein folding/aggregation, he served there as Head of the Cellular Biochemistry Unit, Head of the Analytical and Preparative Cytometry Facility, Chairman of the Scientific Council, member of the Board, Scientific Director… Simultaneously (1968-1998), Michel Goldberg was Professor at the Paris University where he taught Advanced Enzymology and Physical Chemistry of Biological Macromolecules, and chaired the PhD Program of Protein Biochemistry. He has been a consultant and/or member of the Scientific Advisory Board of several companies in France (Genetica, Moet-Hennessy, Christian Dior Perfumes, Ely Lilly –France) and abroad (Ely Lilly USA, Senomyx USA, OMNIS Biotecnologia Brazil). He is currently member of the International Board of the Weizmann Institute of Science (Rehovot - Israel), Chairman of the Scientific Council of the Pasteur-Weizmann Association and member of the Advisory Board of the Institute of Biotechnology and Bioinformatics in Natal, Brazil). He is member of the Biophysical Society (USA), of the Protein Society (USA) and of the European Molecular Biology Organization. He received a Prize from the Alexander von Humboldt Foundation and a Max Planck Research Prize.
Pascal Brandys is co-founder, Chairman and CEO of CompuVax, a leader in computational engineering of vaccines. Mr. Brandys has a 30-year extensive and successful global experience in the biotechnology industry and international finance. Previously Mr. Brandys was President and Managing Director of Biobank Technology Ventures LLC and also Chairman and CEO of Genset, a genomics company he co-founded in 1989 and grew to a market capitalization of over $1.5 billion before its acquisition by Merck-Serono in 2002. Mr. Brandys has held numerous corporate directorships in public and private companies, most notably NASDAQ listed Innogenetics NV, ILOG SA, and Ceres, Inc. Mr. Brandys was also a pioneer in biotechnology investments in Europe and Japan as CEO of Unihon Services in Tokyo and Partner of Eurocontinental Ventures in London during the eighties. Mr. Brandys is a graduate of the Ecole Polytechnique of Paris and holds an MS in Economic Systems from Stanford University. Mr. Brandys was also the founding President of France Biotech, the French biotechnology trade association and he received the Outstanding Service to Biotechnology Award from the European Life Sciences Partnering Foundation.